Registry of Lobbyists
Version 10 of 74 (2007-01-29 to 2007-07-20) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
| Corporation: |
GlaxoSmithKline
7333 Mississauga Road Mississauga, ON L5N 6L4 Canada |
| Telephone number: | 905-819-3000 |
| Fax number: | 905-819-3099 |
| Responsible officer name and position during the period of this registration: | Paul Lucas, President and CEO |
| Description of activities: | GLAXOSMITHKLINE IS ONE OF CANADA'S LARGEST RESEARCH-BASED PHARMACEUTICAL COMPANIES. GLAXOSMITHKLILNE OPERATES FOUR MAIN FACILITIES IN CANADA, INCLUDING ITS HEAD OFFICE AND MANUFACTURING OPERATIONS IN MISSISSAUGA, AND ITS BUREAU D'AFFAURES DU QUEBEC IN MONTREAL. IN TOTAL GLAXOSMITHKLINE EMPLOYS APPROXIMATELY 1,800 PEOPLE ACROSS THE COUNTRY. GSK IS A LEADER IN MANY IMPORTANT THERAPEUTIC AREAS, INCLUDING RESPIRATORY, CENTRAL NERVOUS SYSTEM, ANTI-INFECTIVES AND GASTRO INTESTINAL/METABOLIC. GLAXOSMITHKLINE INVESTS MORE THAN $100 MILLION IN RESEARCH & DEVELOPMENT IN CANADA EACH YEAR. GLAXOSMITHKLINE'S $120 MILLION MANUFACTURING OPERATIONS PRODUCE MORE THAN 100 MEDICINES AND 20 MILLION UNITS ANNUALLY. |
| The client is a subsidiary of the following parent companies: |
GlaxoSmithKline plc
980 Great West Road Brentford, Middlesex TW89GS United Kingdom |
| Coalition | The corporation is not a member of a coalition. |
| Subsidiary: | The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking. |
| Other direct interests | The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking. |
| Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | No |
| Name: | Bryan Jones |
| Position title: | Manager, Public Policy |
| Public offices held: | Yes |
| Name: | Jacqueline LaRocque |
| Position title: | Manager, Public Policy |
| Public offices held: | Yes |
| Name: | Geoff Mitchinson |
| Position title: | Vice President, Public Affairs and Reimbursement |
| Public offices held: | No |
| Name: | Grant Perry |
| Position title: | Director, Federal Affairs and Reimbursement |
| Public offices held: | Yes |
| Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | Aboriginal Affairs and Northern Development Canada, Atlantic Canada Opportunities Agency (ACOA), Canadian International Development Agency (CIDA), Canadian International Trade Tribunal (CITT), Competition Tribunal (CT), Federal Office of Regional Development – Quebec (FORD[Q]), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Industry Canada, Members of the House of Commons, National Research Council (NRC), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Works and Government Services Canada, Revenue Canada (RC), Technology Partnerships Canada (TPC), Treasury Board Of Canada Secretariat (TBS) | ||||||
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Grass-roots communication, Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format | ||||||
| Subject Matter: Areas of Concern: | Constitutional Issues, Consumer Issues, Employment and Training, Financial Institutions, Government Procurement, Health, Industry, Intellectual Property, Internal Trade, International Relations, International Trade, Labour, Regional Development, Science and Technology, Taxation and Finance | ||||||
| Subject Matter: Retrospective: | ANY LEGISLATIVE PROPOSALS, POLICIES OR PAPERS, BILLS OR RESOLUTIONS, OR REGULATIONS THAT WOULD IMPACT THE BRAND NAME PHARMACEUTICAL INDUSTRY OR THE REVIEW OF ANY DRUG PATENT LEGISLATION; PHARMACARE OR HOME CARE PROGRAMS; NATIONAL PHARMACEUTICALS STRATEGY, DRUG APPROVALS POLICIES AND PROCESSES AS WELL AS GOVERNMENT PURCHASES OF VACCINES. | ||||||
| Subject Matter: Prospective: | ANY LEGISLATIVE PROPOSALS, POLICIES OR PAPERS, BILLS OR RESOLUTIONS, OR REGULATIONS THAT WOULD IMPACT THE BRAND NAME PHARMACEUTICAL INDUSTRY OR THE REVIEW OF ANY DRUG PATENT LEGISLATION; PHARMACARE OR HOME CARE PROGRAMS; DRUG APPROVALS POLICIES AND PROCESSES AS WELL AS GOVERNMENT PURCHASES OF VACCINES. | ||||||
Details Regarding the Identified Subject Matter
|
|||||||